On the Role of the Health Technology Assessment Council in COVID-19 vaccination Released on 28 June 2022 This is a clarification on the role of the Health Technology Assessment Council (HTAC) in the nationwide COVID-19 vaccination program. For any COVID-19 vaccine dose to be rolled out, there must be, in this sequence, (1) an Emergency Use continue reading : On the Role of the Health Technology Assessment Council in COVID-19 vaccination
DOH, HTAC Guidance on COVID-19 Boosters and Fourth Dose for Healthcare Workers, Senior Citizens, and the Immunocompromised Population
On 17 June 2022, the Secretary of Health signed the updated recommendation of the Health Technology Assessment Council (HTAC) for second booster of COVID-19 vaccines for healthcare workers, senior citizens (ages 60 years old and above), and fourth dose for the immunocompromised population, following the Disease Prevention and Control Bureau’s (DPCB) rollout. Considering the role of continue reading : DOH, HTAC Guidance on COVID-19 Boosters and Fourth Dose for Healthcare Workers, Senior Citizens, and the Immunocompromised Population
Eribulin for Metastatic Soft Tissue Sarcoma (mSTS)
Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF Document link: Evidence summary on eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via https://hta.doh.gov.ph/topic-nomination/.) Document Preview:
Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF
Document link: Evidence Summary (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via Topic Nomination.)